SCHEMBL11945316

SCHEMBL11945316

CC1(COc2c(N3CCN(S(=O)(=O)c4ccc(CNC(=O)c5ccccc5)s4)CC3)cnn(-c3cccc(Cl)c3)c2=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ POLB P06746 2/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ NCOA2 Q15596 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ MAPK9 P45984 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ MAPT P10636 1/20 0.39
▸ ALDH1A1 P00352 6/20 0.39
▸ BCL2 P10415 1/20 0.39
▸ BCL2L1 Q07817 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ DCTPP1 Q9H773 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945318 0.92 POLB (0.44) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11945337 0.84 POLB (0.45) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11944747 0.83 POLB (0.58) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11946365 0.81 MAPT (0.43) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11945919 0.81 POLB (0.39) KMT2APOLBNPSR1CYP3A4CYP2C19
SCHEMBL11945365 0.81 ALDH1A1 (0.46) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11945928 0.80 POLB (0.42) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11945363 0.80 NPSR1 (0.43) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11945339 0.80 NPSR1 (0.43) MEN1KMT2APOLBNPSR1CYP3A4
SCHEMBL11945431 0.80 POLB (0.51) MEN1KMT2APOLBNPSR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MEN1 1830/4885KMT2A 3312/4885POLB 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback